Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;10(4):518-521.
doi: 10.21037/hbsn-2021-13.

Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide

Alessandro Mantovani  1 , Giovanni Targher  1
Affiliations
Editorial

Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide

Alessandro Mantovani et al. Hepatobiliary Surg Nutr. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/hbsn-2021-13). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Possible hepatoprotective effects of GLP-1RAs for treatment of NAFLD or NASH. GLP-1RAs, glucagon-like peptide-1 receptor agonists; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.
See this image and copyright information in PMC

Comment on

References

    1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. 10.1016/S0140-6736(20)32511-3 - DOI - PubMed
    1. Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019;69:2672-82. 10.1002/hep.30251 - DOI - PubMed
    1. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. 10.1016/S2468-1253(21)00020-0 - DOI - PubMed
    1. Mantovani A, Petracca G, Beatrice G, et al. Nonalcoholic Fatty Liver Disease and Risk of Incident Diabetes Mellitus: An Updated Meta-Analysis of 501,022 Adult Individuals. Gut 2021;70:962-9. 10.1136/gutjnl-2020-322572 - DOI - PubMed
    1. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 2020. doi: . [Epub ahead of print].10.1136/gutjnl-2020-323082 - DOI - PubMed